MicroRNAs (miRNAs or miRs) are evolutionally conserved, small non-coding RNAs that regulate gene expression at the posttranscriptional level. They guide an Argonaute-containing multiprotein complex to specific messenger RNAs by binding to partially complementary sequences in the 3 untranslated regions (3 UTRs), thereby suppressing translation and/or inducing mRNA decay 1 . Each miRNA gene gives rise to a stem-loop precursor, which on processing, generates miR-5p and miR-3p strands. Depending on their relative stabilities, they are conventionally termed guide (miR) or passenger (miR * ) strands. Although many miR * s are degraded, some are stable, and because miR/miR * harbour distinct seed sequences, each will target a largely non-overlapping mRNA cohort.
Known as key regulators of stem cell (SC) physiology and pathology, miRNAs change patterns markedly on cell fate alteration, including during malignant progression. As a cohort, miRNAs can aid in stratifying cancer subtypes and patient prognosis, rendering them attractive biomarkers 2 . A few of these cancer-associated miRNAs act as functional drivers in tumour progression and/or maintenance [3] [4] [5] . This is also true for squamous cell carcinomas (SCCs), lifethreatening and metastatic cancers that occur frequently in stratified epithelia of the head and neck, oesophagus, lung, and skin, where miR-21, miR-203 and miR-125b have been shown to functionally impact tumorigenicity [6] [7] [8] [9] [10] .
The complexity of differentially expressed miRNAs and their targets poses significant hurdles in evaluating not only their causeversus-consequence roles in cancer progression, but also their relative degrees of potency in exerting their effects. Although individual oncomiRs have been characterized in vivo, so far, the functional significance of a cancer-associated miRNA pattern has not been interrogated in an unbiased fashion in a physiological context. Prerequisites to such analyses are first, high-throughput sequence analyses to elucidate the expression dynamics of miRs and miR * s in tumour-initiating cells of the cancer; second, a robust, strand-specific miRNA expression platform compatible with functional genomics; and finally, an in vivo system for rapid functional screening of a large pool of relevant miRNAs in a particular cancer. Our current study explores these possibilities and performs a strand-specific in vivo screen of cancer-associated miRNAs to unveil key drivers and their oncogenic targets in SCCs.
RESULTS

In vivo miRNA landscapes of stem cells in homeostasis and SCCs
We began by performing miRNA deep sequencing on basal epithelial cells purified by fluorescence-activated cell sorting (FACS) from HRas-induced, pathology-diagnosed malignant SCCs, where basal cells (BCs) are known to be enriched for tumour-initiating potential [11] [12] [13] . Similar analyses were carried out on adult and/or embryonic progenitors of normal epidermis and hair follicles (HFs; Supplementary Fig. 1a-c) . Hierarchical clustering based on miRNA expression levels partitioned these populations into three main groups (Fig. 1a) , exposing a dynamic miRNA landscape in SCCs versus normal SC-enriched populations.
One hundred and sixty-nine miR/miR * s were abundantly expressed in SCCs. Differential expression analysis for sequence count data 14 (DESeq) identified 97 of these miRs and 11 miR * s that changed by ≥2× (P < 0.05) in SCC-BCs relative to normal adult and/or embryonic counterparts ( Fig. 1b and Supplementary  Fig. 1d and Supplementary Table 1) . A number of miRNAs previously implicated in epithelial cancers, including SCCs, were on our SCC signature [6] [7] [8] [9] [10] . The physiological relevance of the rest of the >100 miR/miR * s remained unexplored. Quantitative PCR (qPCR) and in situ hybridizations (ISH) validated and further documented these patterns ( Supplementary Fig. 1e,f) . Intriguingly, some miRNAs were expressed in embryonic and normal skin, but declined during tumorigenesis; others were induced at the benign (papilloma) stage or became more prominent in invasive SCCs (Fig. 1c) . These patterns underscored the remarkable responsiveness of cancer-associated miRNA genes to various stimuli throughout different stages of development and tumorigenesis.
In vivo screen identifies SCC-driving miRNAs
Previous studies show that gene expression, hence probably miRNA expression, in SCs is highly sensitive to the niche microenvironment 15 .
Assessing the functional relevance of this myriad of tumour-associated miRNAs thus necessitated an in vivo strategy. Compounding this hurdle is the need for a lentiviral miRNA-expression backbone to faithfully and efficiently express the unique miR or miR * strand independently of the other.
Termed small accurate (SA)-miR, our vector used an optimized, artificially engineered precursor backbone to express either side of the unprocessed stem-loop (Fig. 2a) . SA-miRs conferred specific expression of the desired strand at ≥2× endogenous levels (Fig. 2b,c) , with high fidelity in the 5 end of the miRNA processing ( Supplementary  Fig. 2a,b) . Reflective of these refinements, SA-miRs exhibited robust activity ( Supplementary Fig. 2c ).
With the expression tools and miRNA landscape in hand, we set out to perform a pooled in vivo functional screen to identify which of the 169 cancer-associated miRs or miR * s can drive skin SCCs. To this end, we first prepared an SA-miR lentiviral (LV) library of our cohort and 5 scrambled (Scr) controls (Supplementary Table 2 ). To control for any nonspecific effects from viral infections, we also made a LV-control library composed of only scrambled SA-miRs (SA-Scr).
We next employed our recently devised technology for LV delivery in utero into the amniotic sacs of E9.5 embryos 16 . This selectively and efficiently transduces single-layered surface epithelium, resulting in clonal expansion and expression in adult skin. Previously, we used this approach to identify protein-coding genes with oncogenic or tumour-suppressor activities 17, 18 . Here, we injected our SA-miR libraries at a multiplicity of infection (MOI) 1 to ensure that no more than one SA-miR gene was stably integrated into the genome of each cell. To achieve robustness, we used a coverage so that ≥100× Multiple cloning site of SA-miR expression vector Figure 2 In vivo tool small accurate (SA)-miR for efficient and faithful miRNA expression. (a) Pri-miR-125b was used as a template to design the SA-miRNA backbone, with the pre-miR terminal loop shortened and an NheI site added for rapid cloning. Asymmetric thermal stabilities were introduced at the two ends to increase the probability of mature strand selection. The sequence of the multiple cloning site of the SA-miRNA expression vector following the U6 promoter is shown; SA-miRNA also carries a H2BGFP cassette driven by the PGK promoter to be used as an internal marker. (b) SA-miRs were transfected into cultured mouse keratinocytes and qPCR was used to quantify their overexpression relative to endogenous levels (black dashed line, SA-scrambled-sequence (SA-Scr)-transduced). In the cases of miR-1 and miR-294, the expression is unusually high owing to the extremely low level of endogenous miRs. At least five biological replicates were performed; shown are mean ± s.d. n = 3 independent experiments. (c) Mouse SCC cells were exposed to lentiviral-based SA-miRs harbouring a GFP transgene, sorted for GFP 2 d later, and subjected to deep sequencing. The relative amount of undesired passenger strand as a percentage of targeted guide strand (set as 100%) is plotted to demonstrate preferential guide strand selection with SA-miRNAs. The reads for each miR had been normalized with that from SA-Scr-transduced cells (which reflect endogenous miR levels) and are presented as sole contributions from the SA-miR vector expression. A different Scrambled sequence was used from the SA-Scr shown in the graph. different E9.5 cells were transduced with the same SA-miR. SA-miR representation was determined through DNA deep sequencing of epidermal progenitors at E12.5 and postnatal day 50 (P50; Fig. 3a) .
Characteristic of most proteins with oncogenic potential, the cancer-associated miRNAs on their own did not exhibit signs of tumours by P50 (Fig. 3b) . We therefore subjected animals transduced with SA-Scr and SA-miR libraries to chemical carcinogenesis with 7,12-dimethylbenz[a]anthracene (DMBA), which typically induces oncogenic Ras mutations 10, 19, 20 and then 12-O-tetradecanoylphorbol 13-acetate (TPA), which leads to benign tumours within 2-4 months, some of which can later progress to SCC.
Indeed, for both SA-Scr-and SA-miR-transduced animals, tumours began to appear within this time frame (Fig. 3b) . Notably, however, both tumour initiation and growth were markedly accelerated in mice transduced with the SA-miR library compared with the SA-Scr (Fig. 3b,c) . Moreover, whereas SA-Scr-transduced tumours exhibited smooth bordered invaginations characteristic of benign papillomas, SA-miR-transduced tumours exhibited features of malignant SCCs, including ill-defined borders, heightened mitoses and stromal invasion ( Fig. 3c and Supplementary Fig. 3a ).
Deep sequencing of integrated strand-specific SA-miR genes revealed evidence of clonal dominance in 79 of 107 independent tumours analysed (Supplementary Table 3 ). Twenty-two of these tumours were enriched for the established oncomiR, miR-21. Unexpectedly, however, was miR-21 * as the second top hit, elevated in 13 tumours (Fig. 3d) . This was not due to passenger strand contamination because miR-21 and miR-21 * were separately encoded by their strand-specific SA-miR vectors (Fig. 2c) . Notably, neither SA-miR-21 nor SA-miR-21
* showed skewed representation in control cohorts (Fig. 3d) . These findings provided compelling evidence that miR-21 * harboured oncogenic activity independent of miR-21. Another intriguing feature of our screen was the independent appearance of tumours that seemed to be fuelled by different members of particular miRNA families, which share a common seed sequence. In this regard, we observed tumour-specific enrichment of miR-10b/99b/100, miR-181a/b/c, miR-200a/141 and miR-200b/200c/429 families ( Fig. 3d and Supplementary Fig. 3b ). Many of these individual miRNAs have been previously implicated in different types of human cancer [21] [22] [23] . As expected of oncomiRs, their clonal domination was not seen in controls (Fig. 3d) . To confirm that miRNAs surfacing in the screen are indeed induced and/or abundant during tumorigenesis, we performed ISH. Consistently, miR-21 and miR-21
* expression was first induced in benign papillomas and further elevated in invasive SCCs; in contrast, miR-200a and miR-200b were detected in normal skin, and remained abundant in tumorigenesis (Fig. 3e) . Their prevalent clonal selection during tumorigenesis and their high expression levels made these miRNAs attractive candidates that drive SCC progression.
Validate candidate oncomiRs in SCCs
To directly test whether miRs and miR * s that surfaced in our screen indeed drive SCCs in a physiological setting, we returned to our in utero infection procedures. We started by testing one well-established oncomiR (miR-21) along with three candidates, namely miR-21 * , miR-200a and miR-200b, which had not been previously implicated in SCCs. This time, we subcloned these SA-miRs into a lentiviral backbone expressing a Cre recombinase (LV-Cre) and infected E9. Recapitulating the in vivo pooled screen yet with faster kinetics than the library, each individual SA-miR promoted tumour progression (Fig. 4a) . These results underscored the efficacy of our approach. The independent effects of miR-21 * were of particular interest, as most in vivo studies that have implicated miR-21 in cancer invariably activate or delete the entire locus 7, 25, 26 . A priori, because the seed sequences share no identity and hence the oncogenic potential of a miR * cannot be inferred from a miR, this observation raises the distinct possibility that miR-21 * may be a contributing factor to some of the previously reported tumorigenic effects.
Importantly, although miR-21 has been reported to upregulate its expression through an auto-regulatory loop 27, 28 , SA-miR-21 did not directly induce miR-21
* expression in our context, and vice versa ( Supplementary Fig. 4a ). In addition, the miR-21 and miR-21 * probes shared little or no homology with each other or any of the other miRNAs on our SCC miR signature list. No background signal was observed in miR-21 knockout skin, thereby validating the specificity of in situ probes ( Supplementary Fig. 4b ). Given its complete absence in normal skin and marked induction in SCCs versus benign papillomas shown are mean ± s.d. n = 3 independent experiments. * P < 0.05, * * P < 0.01.
( Fig. 4b) , we decided to further investigate the possible role of miR-21 * in cancer.
Notably and in contrast to benign papillomas formed in LV-Cre-SA-Scr-transduced LSL-HRas G12V animals, miR-21-and miR-21
* -transduced tumours frequently exhibited irregular edges with discontinuous integrin β 4 immunolabelling (Fig. 4c ).
Other signs of invasiveness included the expansion of the basal marker keratin K5, loss of the differentiation marker K10, and an expanded domain of proliferation as measured by S-phase-specific incorporation of the nucleotide analogue EdU (Fig. 4c,d ). In line , were transduced with SA-miRs to generate isogenic SCC lines that express miR-21, miR-21 * , neither or both. Engraftment of these lines revealed that relative to Scr (control) and the parental SCC (pSCC, generated with sgRNA-Scr alongside sgRNA-miR), each strand possessed tumour-forming ability. Without them, tumorigenesis was severely compromised; together, they restored tumorigenicity to full capacity. Two-way ANOVA with repeated measurement was performed. Shown are mean ± s.d. n = 3 independent experiments. Log-rank Mantel-Cox test was used. * P < 0.05, * * P < 0.01. NS, not significant. (e) Allograft competition assay. Test (GFP marked) and control (RFP marked) cells are mixed at equal ratios, combined with Matrigel and then transplanted into the backskins of Nude mice. Emerging tumours (>1 cm) are then subjected to FACS analysis to gauge efficiency of contribution of test and control cells to the tumours. In this assay, a red and green control population behave similarly but test cells that have lost the miR-21 locus or with one strand restored are outcompeted or partially rescued, respectively. For b,e, paired t-tests were used to compare edited cells with parental cells. At least three biological replicates were performed; shown are mean ± s.d. n = 3 independent experiments. * P < 0.05, * * P < 0.01.
with these in vivo observations, HF-SCs isolated from healthy mice transduced with either miR-21 or miR-21 * showed enhanced colony formation efficiency in culture ( Supplementary Fig. 4c ). Moreover, under suspension conditions that normally halt proliferation and induce apoptosis (anoikis), primary mouse keratinocytes transduced with miR-21 or miR-21 * showed protection, with the most significant effect observed from co-expression of both strands ( Supplementary Fig. 4d ).
To completely uncouple the two miRs, we first disrupted the endogenous miR-21/miR-21 * locus in malignant mouse SCC cells using CRISPR/CAS technology 29 , thereby obliterating expression of both miRs (Fig. 5a,b and Supplementary Fig. 5 ). As expected, ablating the locus ( SCC) significantly crippled tumorigenic activity of parental SCCs (pSCCs) in grafting experiments (Fig. 5c,d ), in line with the previously reported oncomiR-21 addiction phenotype in lymphoma 26 . Notably, re-expressing miR-21
* or miR-21 on its own partially rescued tumour initiation and growth as judged by limiting dilution assays and time course analyses, respectively ( Fig. 5b-d) . Additionally, expressing both miRs together restored full-blown SCC growth (Fig. 5d) , arguing against off-target effects (see Methods). Interestingly, in a competition assay, when SCCs ± SA-Scr, SA-miR-21 or SA-miR-21
* was combined at equal ratios with pSCC + SA-Scr and then transplanted, pSCC cells remained the primary contributors to tumour growth (Fig. 5e ), underscoring the cell-autonomous roles of miR-21 and miR-21 * . Together, these findings provided compelling evidence that miR-21 * drives tumorigenesis independent of miR-21, and both strands are essential for sustaining malignant growth.
miR-21
* is a physiologically relevant oncomiR in human Analysis of ISH and The Human Cancer Genome Atlas (TCGA) revealed high miR-21 and miR-21 * in human head and neck SCCs (HNSCC) relative to neighbouring non-phenotypic tissue (Fig. 6a,b) . miR-21
* was also elevated in other epithelial cancers, haematolymphoid malignancies and sarcomas (Fig. 6c) . Although lower than miR-21, miR-21 * levels are considerably higher than passenger strands of most established oncomiRs and tumourabundant miRs (Supplementary Fig. 6a) . Consistently, only miR-21
* , and to a much lesser extent miR-615 * , scored among all of the passenger strand miR * s in our library (Supplementary Table 3 ). Interestingly, whereas miR-21 remained invariably high in human SCCs, miR-21 * levels intriguingly varied across >2-log values in these cancers, despite their co-transcription and processing. Specifically, HNSCC patients with the highest miR-21 * levels, but not with high miR-21, trended towards poorer prognosis (Fig. 6d,e and Supplementary Fig. 6b ). For a, at least three biological replicates were performed; shown are representative images. Scale bar, 100 µm. For b, unpaired t-test was used, shown are mean ± s.d. n = 31 for normal tissues and n = 263 for tumours. (c) miRNA sequencing data from the TCGA database show that miR-21 * is expressed in many types of cancer 35 including breast invasive carcinoma (BRCA), diffuse large B-cell lymphoma (DLBC), acute myeloid leukaemia (LAML), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), pancreatic ductal adenocarcinoma (PAAD), prostate adenocarcinoma (PRAD), sarcoma (SARC) and cutaneous melanoma (SKCM). Illustrated on the same graph are expression levels of many tumourassociated-miRs whose corresponding miR * s were not similarly stabilized. An exception was miR-143 * in PRAD. Box plot maxima, minima and centre are defined at highest, lowest reads and reads at medium. n = 3 tumours. (d) miR-21 * (orange) is considerably more variable than miR-21 (red) in human SCCs (left panel). However, whereas miR-21 is uniformly high, patients with the highest miR-21 * expression show a trend towards decreased survival (right and middle panels). Pearson r correlation test was performed. n = 303 and 277 for miR-21 * and miR-21, respectively. (e) Tissue array in situ hybridization data were divided into high, low or no expression groups, and correlated with patient tumour grades and stages. Strong miR-21 * (but not miR-21) expression was associated with more advanced tumours. n = 49, 20 total for grade tumours, and n = 20, 52 total for stage tumours. Binomial test was used. * * P = 0.0098 for miR-21 * grades, * P = 0.0100 for miR-21 * stages. NS, not significant. Supplementary  Fig. 9 . (g) Increased EdU labelling and proliferation from SA-miR-21 * overexpression or Phactr4 knockdown in keratinocytes under resuspension growth. For d-g, at least three biological replicates were performed. Shown are mean ± s.d. n = 3 independent experiments. Paired t-test was performed.
* P < 0.05, * * P < 0.01. NS, not significant.
To test whether the elevated expression of miR-21 * is physiologically relevant to human cancer as it is for mouse SCC, we applied our lentiviral SA-miR to human SCC (FaDu) cells as well as human immortalized epithelial (HaCaT) cells, a line that behaves more similarly to normal human epidermal keratinocytes. We then xenografted them into immunocompromised (Nude) mice. Interestingly, elevating miR-21
* by ∼4-5× accelerated tumour growth of FaDu cells over controls and induced the potential of HaCaT cells to undergo de novo tumorigenesis (Fig. 6f,g and Supplementary Fig. 6c) . Notably, the miR-21 * strand on its own was comparable to that of miR-21 in stimulating tumour growth even though both miRNAs required additional oncogenic hits to elicit their tumour-promoting effects. In addition, disrupting the miR-21 locus in human A431 SCCs by CRISPR/CAS suppressed their tumorigenesis in xenografts, suggesting a conserved function of this locus in sustaining malignant growth in human SCCs ( Supplementary Fig. 6d-f) .
Our focus on the HRas mutant background to examine miR-21 * oncogenic potential is most relevant because 25% of human HNSCCs and 30% of lung SCC patients show alterations (mutation or amplification) in the RAS/MAPK pathway. It is possible that miR-21 * interacts with additional oncogenic pathways, given that HaCaT cells harbour p53 mutations and A431 cells have EGFR amplifications. Although interesting, this goes beyond the scope of our current study.
* directly targets Phactr4 and regulates Rb/E2F To identify miR-21 * targets that are responsible for its tumorigenic effects, we perused the TCGA database and found >7,500 mRNAs that are changed by >2× in HNSCCs versus their normal tissue counterparts (Supplementary Table 4 ). Applying TargetScan and http://microRNA.org 30, 31 , we identified 67 SCC-downregulated (≥2×) genes as putative targets of miR-21 * (Supplementary Table 5 ). Of these, nine showed significant (P < 0.05) inverse correlations with the levels of miR-21 * across SCCs (Fig. 7a,b and Supplementary  Fig. 7a-c, Supplementary Table 6 ). Similar analyses revealed six different putative targets of miR-21, including a previously reported miR-21 target in epithelial cancers 32 ( Supplementary Fig. 7a-c) . Given the seemingly poorer prognosis of TCGA HNSCC patients expressing the highest miR-21 * levels, we concentrated our efforts on putative miR-21 * targets. PHACTR4 (phosphatase and actin regulator 4) was particularly intriguing in that it was not only repressed in HNSCC patients with high miR-21 * levels, but also when diminished, significantly associated with poor prognosis among HNSCC patients (Fig. 7a,b) . Notably, PHACTR4 had previously surfaced in an in vitro screen for genes that antagonize the proliferation of immortalized mammary epithelial cells, and reduced growth of cancer lines in xenografts 33 .
The predicted miR-21
* -binding site on the Phactr4 3 UTR is conserved between mouse and human (Fig. 7c) . Moreover, miR-21 * Figure 8 Phactr4 is a main mediator of oncomiR-21 * activity in vivo.
(a) Phactr4 knockdown by 2 shRNAs in vivo phenocopies miR-21 * overexpression in promoting tumorigenesis. Phactr4 shRNA hairpins were subcloned into LV-Cre virus and used to transduce LSL-HRas G12V mice using our in utero procedure. n = 8 mice for Scr cohort; n = 14 mice for shRNA1 cohort, n = 10 mice for shRNA2 cohort. Paired t-test was performed for qPCR measurement. Log-rank Mantel-Cox test was used for survival analysis. (b) Loss of miR-21 * inhibited tumour formation ( SCC-SA-miR-21 + Scr shRNA, grey line), whereas Phactr4 knockdown fully restored its tumour formation efficiency ( SCC-SA-miR-21 + Phactr4 shRNA, orange line) and further enhanced pSCC tumorigenicity (pSCC + Phactr4 shRNA, purple line). Two-way ANOVA with repeated measurement was performed. (c) Elevating Phactr4 suppresses the tumorigenic activity of miR-21 * . The wild type but not the mutant version lacking the PP1-binding domain (Phactr4 PP1) of Phactr4 overexpression reversed the enhanced tumorigenesis mediated by SA-miR-21 * . Two-way ANOVA with repeated measurement was performed. (d) SCC-Phactr4 MBS cells, generated by CRISPR/CAS-mediated deletion of the predicted miR-21 * targeting site on the endogenous Phactr4 3 UTR, were subjected to SA-Scr or SA-miR-21 * expression, followed by Phactr4 level measurement using qPCR, or allograft assays. Phactr4 MBS SCCs cells were no longer sensitive to miR-21 * regulation. Paired t-test was performed for qPCR. Two-way ANOVA with repeated measurement was performed for tumour growth. For a-d, at least three biological replicates were performed; shown are mean ± s.d. n = 3 independent experiments. * P < 0.05, * * P < 0.01. NS, not significant.
suppressed the activity of a luciferase reporter containing the Phactr4 3 UTR as well as the wild type (wt), but not mutant (mut), version of the predicted miR-21 * -binding site (MBS; Fig. 7d ). Consistent with Phactr4 as a direct target of miR-21 * , the endogenous levels of Phactr4 were diminished in primary mouse keratinocytes when cells were transduced with SA-miR-21 * (Fig. 7e and Supplementary Fig. 8a ). This regulation on Phactr4 was specific to miR-21 * and was not observed with miR-21. Finally, if Phactr4 is a bona fide miR-21
* target, its levels should be de-repressed in our CRISPR/CAS-edited isogenic SCC line that specifically lacked miR-21 * ( SCC+SA-miR-21). This was indeed the case (Fig. 7e) . Mechanistically, the ability of miR-21 * to target Phactr4 resulted in the phosphorylation and inactivation of the Rb tumour suppressor, which in turn led to upregulation of E2F/Rb targets and enhanced cell proliferation (Fig. 7f,g ). It has been proposed that PHACTR4 regulates protein phosphatase 1 (PP1) thereby controlling RB phosphorylation 34 . We return to this point below.
The tumorigenic activity of miR-21
* is mediated by Phactr4 Finally, to test whether Phactr4 is a physiological mediator of the tumorigenic activity of miR-21
* in vivo, we knocked down Phactr4 in skin progenitors in utero with two independent short hairpin RNA (shRNA) hairpins, and then challenged the adult mice to HRAS-induced tumorigenesis. Notably, although neither Phactr4 shRNA caused tumorigenesis on its own, both promoted HRASinduced tumorigenesis, phenocopying miR-21 * overexpression in vivo (Fig. 8a) . Remarkably, Phactr4 knockdown was also sufficient to restore the tumorigenic properties of CRISPR/CAS-mediated miR-21
* -deficient cells in allografts (Fig. 8b) . To test whether the effects of Phactr4 are truly linked to miR-21 * and significantly contribute to the activity of miR-21 * as an oncogenic driver in SCC, we re-expressed Phactr4 lacking its 3 UTR and examined the consequences on miR-21 * -driven tumorigenesis. As shown in Fig. 8c , this miR-21 * -refractile Phactr4 suppressed SA-miR-21
* -driven tumorigenesis in engraftment assays. To rule out confounding problems caused by the complete absence of the 3 UTR of Phactr4, we used CRISPR/CAS to delete only the miR-21 * target site within the endogenous Phactr4 3 UTR. Of significance, in the Phactr4 mutant SCC cell clones, not only the level of Phactr4 becomes resistant to miR-21 * regulation, but also these SCCs are no longer sensitive to the tumour-promoting effects of miR-21
* overexpression (Fig. 8d) . Additionally, in line with the regulation of RB by PHACTR4 via PP1, a mutant version of PHACTR4 lacking its PP1-interacting domain 34 , even though expressed at a comparable level to WT, largely lost its suppressive effects on the tumorigenic activity of miR-21 * (Fig. 8c and Supplementary Fig. 8b ). Together, these pieces of evidence strongly corroborated Phactr4 as a key and direct mediator of the tumorigenicity of miR-21 * in SCCs.
DISCUSSION
We began these studies by profiling the miRNAs that distinguish malignant SCC stem cells from their normal skin counterparts. We then built robust SA-miR tools and executed a functional assay in mice to screen 169 different cancer-associated miRNAs for the ones that contribute to the rapid progression from benign papillomas to malignant SCCs. This illustrates, to our knowledge, the first study that applies functional genomics to simultaneously interrogate a cohort of miRNAs in vivo for their relative functional importance. Of the 169 miRNAs screened, only a few exhibited strong tumorigenic potential in our assay, suggesting that these miRNAs play special roles in malignant progression. Remarkably, 20% of the tumours analysed exhibited a strong bias towards miR-21. Finding miR-21, as well as miR-10b and miR-125b, in this handful of tumourenhancing miRNAs demonstrated the robustness of our system, as these are well-established oncomiRs of epithelial cancers 10, 21, 26 .
What was unexpected was the appearance of miR-21
* and miR-200 family members as strand-specific drivers in malignancy. miR-21
* , independently of miR-21, was especially potent with 12% of the tumours exhibiting clonal dominance for this miRNA. Moreover, although miR-21 is a well-established oncomiR with well-defined targets, relatively little was known about its passenger strand. Its appearance as a top hit in our screen took on all the more significance in that miR-21 * also associated with poor patient prognosis in human SCCs.
By exploiting the TCGA database and applying both CRISPR/CAS and rapid lentiviral-based genetics to skin and head and neck epithelia in mice, we verified the miR-21-independent tumorigenic activity of miR-21 * and uncovered Phactr4 as a key target whose suppression confers much of the oncogenic activity of this hitherto ignored miRNA. PHACTR4 is one of four members of a family of PP1-and actin-binding proteins. Although it has been implicated in integrin-mediated cell migration 34 , it has only recently been implicated in cancer, where it surfaced in an in vitro RNAi screen for genes that restrain normal cell proliferation 33 . Here, we substantiate in SCCs its implicated actions through PP1-and RB-dependent pathways, but most importantly, link its regulation at least in part to miR-21
* . In summary, we have unravelled the physiological relevance of a potent tumour-enhancing miRNA, miR-21
* , that was masked within one of the most critical loci implicated in cancer. The physiological link to cancer between this little-studied miRNA and one of its targets, also poorly explored, merits further attention in the future. Overall, these findings underscore the importance of taking an unbiased in vivo screening approach to simultaneously and comparatively interrogate the functional significance of a complex signature of miRNAs, regardless of strand identity, that are associated by expression with a particular state, in this case malignant progression.
METHODS
Methods and any associated references are available in the online version of the paper. 7 . For in utero injections, pregnant females were used at E9.5. For the rest of the experiments, treatments on both males and females were started at adult age of P50 (second telogen).
Animal care and use. All animal experiments were performed in the AAALACaccredited Comparative Bioscience Center at The Rockefeller University. Experiments were in accordance with NIH guidelines for Animal Care and Use, approved and overseen by The Rockefeller University's Institutional Animal Care and Use Committee.
Fluorescence-activated cell sorting (FACS) and analysis. Purification of embryonic progenitor populations was performed using K14-H2BGFP (E12, P0) and Lhx2-EGFP (E17) transgenic mice. Purification of adult populations was performed using K14-H2BGFP mice. Purification of tumour populations was performed using WT background, DMBA/TPA-treated tumour cell transplants (papilloma) or TGFβRII-deficient background, DMBA/TPA-treated tumour cell transplants (SCCs). Cell suspensions were from skins/tumours of transgenic animals expressing the basal progenitor marker K14-H2BGFP or the hair placode marker Lhx2-GFP (for E17 HF). Cells were first gated against DAPI to exclude dead cells, and then with forward and side scatters to gate for singlets. Lineage-negative gating was as follows: CD31 for endothelial cells, CD45 for immune cells, CD117 for melanocytes, and CD140a for fibroblasts. E12 epidermal (epi) progenitors were further gated as α6 + K14-H2BGFP + , E17 epi progenitors α6 + Lhx2-GFP − , E17 placodes α6 + Lhx2-GFP + , P0 epi progenitors α6 + K14-H2BGFP + Sca1 + , P0 hair follicle (HF) progenitors α6 + K14-H2BGFP + Sca1 − , adult P28 epiSCs α6 + K14-H2BGFP + Sca1 + CD34 − , HF-SC α6 + K14-H2BGFP + Sca1 − CD34 + , outer root sheath (ORS) α6 + K14-H2BGFP + Sca1 − CD34 − . Tumour grafts formed from previously characterized aggressive or non-aggressive tumour cells were gated as α6
Hi β1
Hi for basal stem cells (BCs) and α6 Lo β1 Lo for differentiated progenies. Whether cultured, or injected directly into recipient mice, these basal SCC cells have been previously shown to have tumour-initiating properties characteristic of cancer stem cells [11] [12] [13] . Our findings here corroborate this behaviour as shown by the tumourinitiating assays in figures throughout the manuscript. For embryonic cell isolation, the backskin was placed dermal side down in dispase (Sigma) for 2 h at 37 • C; for adult or tumour cell isolation, the backskin (dermis side down) or tumour (chopped) was placed in collagenase (Sigma, 0.25% in HBSS) for 1 h at 37 • C. The dermal fractions were collected by scraping the dermal side using a scalpel. The remaining epidermal side (embryo and adult) or cell mixture (tumour) was then transferred to trypsin (Gibco, 0.25% in PBS) at 37 • C for 10 min. Single-cell suspensions were obtained by scraping the skin (adult) or pipetting (embryo and tumour) gently. The cells were then filtered with 70 µM followed by 40 µM strainers, and pelleted at 300 g 4 • C. For FACS analysis, cells were first stained with Live/Dead Blue (Life Tech, 1:100) and Annexin-Pacific Blue (Life Tech, 1:100), and then fixed, permeabilized, stained with anti-GFP (1:1,000), anti-K5 (1:1,000) or anti-K10 (1:1,000), followed by Click-iT reactions and Alexa Fluor staining. For FACS sorting, cell suspensions were incubated with the appropriate antibodies for 30 min on ice. The following antibodies were used: CD34-eFluor660 (1:100, eBioscience 50-0341-80),α6-PE (1:100, BD Bioscience 551129), β1-Alexa647 (1:1,000, eBioscience 14-0291-81), Sca1-PerCP_Cy5.5 (1:1,000, eBioscience 45-5981-80), CD140a-PE_Cy7 (1:100, eBioscience 14-1401-81), CD31-PE_Cy7 (1:1,000, eBioscience 25-0311-81), CD117-PE_Cy7 (1:1,000, eBioscience 25-1171-82), CD45-APC_eFluor450 (1:1,000, eBioscience 48-0451-80). DAPI (0.2 µg ml −1 ) was used to exclude dead cells. Sorting was performed on a BD FACSAria II equipped with Diva software (BD Biosciences). Analyses were performed on LSRII FACS analysers and FlowJo. miRNA sequencing, hierarchical clustering and differential expression analysis. FACS-purified cell populations were lysed in TrizolLS (Invitrogen), and total cellular RNAs were isolated with Direct-zol RNA MiniPrep kit (Zymo Research) and submitted to Weill Cornell Medical College Genomics Resources Core Facility for IlluminaTruSeq Small RNA Sample Preparation and miRNA sequencing (HiSeq2000 Single Read, 51 Cycles). Raw reads are then mapped to miRBase v16 with Python. All 226 mouse-expressed miRNAs, using 100 RPMM (reads per million miRNAs mapped) as the cutoff, were then input into Clustering and Treeview to generate an expression heatmap. The DESeq R package was used to generate lists of differentially expressed miRNAs. SCC-SC-expressed miRNAs were compared with either embryonic or adult SC populations. Dispersions (variability) for each miRNA were estimated using a local fit to the data for each sample, and miRNAs with a P value <0.05 by the negative binomial test were considered for downstream analysis. Differentially expressed miRNAs with fold change (FC) >2 (upregulated, UP) or <0.5 (downregulated, DOWN) were further filtered to retain conserved miRNAs between mouse and human, resulting in SCC-SC signature miRNAs. miRNA real-time PCR and in situ hybridization. miRNA quantitative PCR was performed with TaqMan MicroRNA Assays (Life Tech) as per the manufacturer's protocol. U6 small RNA is used as a loading reference. Skin squamous cell cancer tissue array (SK802a) was obtained from US Biomax. miRNA in situ hybridizations in skin were performed as previously described 36 . Briefly, frozen sections (mouse normal backskin or tumour) were fixed with 4% PFA in PBS for 20 min, or deparaffinized (human tissue array) with sequential ethanol washes, and subjected to 10 min acetylation followed by 10 min proteinase K (5 µg ml −1 ) treatment. At 50 • C, sections were pre-incubated with hybridization buffer for 4 h before incubation with miRNA probes (Exiqon miRCURY LNA Detection probe, 3 end DIG-labelled with Roche labelling kit) at 0.1 µM overnight, and then washed with 5× SSC followed by 3 washes in 0.2× SSC for 30 min each. Sections were then equilibrated at room temperature with B1 buffer, blocked for 1 h, incubated with anti-DIG antibody (Roche 11333062910, 1:2,000) at 4 • C O/N, washed with B1 buffer followed by B3 buffer, and developed with BM Purple (Roche). Bright field images were acquired on a Leica Axioskop2 using a 10×/0.8 air objective.
In vivo pooled screen using SA-miRNA library. The lentiviral SA-miRNA plasmids were constructed from the pLKO.1 backbone. Lentiviral LV-Cre-SAmiRNA plasmids were constructed using LV-Cre (ref. 16 ) and SA-miRNA. miRNAs that were more than twofold upregulated in SCC-SCs compared with either embryonic progenitors or adult SCs (SCC-SC UP signature, 75 cloned) or were expressed above the cutoff (100 RPMM, 94 cloned) in any of the populations sequenced were cloned into the SA-miRNA vector, along with Scrambled control sequences (5 cloned). One hundred and seventy-four library clones (Supplementary  Table 2 ) were then pooled and maxi-prepped DNA was used for higher-titre lentivirus production as previously described 16 . The library was titred to achieve a 15% infection rate measured by FACS analysis. The control library composed of SA-Scramble alone was similarly packaged and titred. At least 10 wild-type C57BL/6 embryos per library were transduced with a theoretical initial coverage = (1.5 × 10 5 surface ectoderm progenitors per embryo) × (15% infection rate)
× 10 embryos/174 library clones = 129-fold. Topical DMBA/TPA treatment was performed as previously described 10 . Briefly, P50 mice in second telogen were shaved and treated with 400 nM DMBA in 100 µl acetone and thereafter, mice were treated with 17 nM TPA in 100 µl acetone twice weekly for 20 weeks. Genomic DNA was isolated from backskin at E12.5 shortly post infection, at P50 tumour onset (starting DMBA/TPA treatment), or in the tumours formed as well as normal backskin at the time of tumour collection with the DNeasy Blood & Tissue Kit (Qiagen), and was used as a template in a 50 µl pre-amplification reaction 30 cycles with 40 indexed SA-miRNA primers (Supplementary Table 7 ) and Phusion High-Fidelity DNA Polymerase (NEB). PCR products were run on a 2% agarose gel, and a clean ∼200 bp band was isolated using Agencourt AMPure XP beads (beckmancoulter) and submitted to the Rockefeller University Genomics Resource Center for Illumina sequencing. Illumina reads were trimmed to the 22-nucleotidelong sequence matching the miRNA position using the FASTX-Toolkit and aligned to the SA-miRNA library with BWA (v0.6.2; ref. 37) using a maximum edit distance of 3 as previously described 17 . Tumours with dominant clones (defined as more than 75% reads mapped to the same miRNA-X) were scored as miRNA-X Tumour. In total 107 tumours were sequenced, with 79 tumours dominated by one or two miRNAs (Supplementary Table 3 ).
Tumour-free survival and tumour growth curves. Wild-type or Hras/Yfp animals were transduced at E9.5 with low-titre SA-miRNA library or LV-Cre-SAmiRNA, respectively. Transduced animals were monitored for 12 weeks, assessed every 2-3 days, and scored positive when tumours were larger than 2 mm in diameter. On P60, tumours were measured along their short and long axis using a digital calliper. Transplantation of mouse SCC or human cells transduced with SAmiRNAs into immunocompromised nude recipients was performed as previously described 10 , and animals were monitored every 3 days for a month. Tumour size was measured using a digital calliper, and tumour volume was calculated using the formula (π(length × width)
2 )/6. For human HNSCC patient data, level 3 miRNAseq data and clinical data were downloaded via DataPortal at The Cancer Genome Atlas (TCGA: http://cancergenome.nih.gov). GraphPad Prism software was used to generate the Kaplan-Meier curves and to calculate the P value for tumour-free survival (mouse) or survival (human) by two-tailed log-rank test.
Immunofluorescence microscopy and immunoblot analyses. The following primary antibodies were used: chicken anti-GFP (1:2,000; Abcam ab13970); guinea pig anti-K5 (1:500; E. Fuchs); rabbit anti-K10 (1:1,000; Covance PRB-159P), rat antiintegrin β 4 (eBioscience 346-11A, 1:1,000), rabbit anti-Phactr4 (Abcam ab192882, 1:1,000) and mouse anti-α-tubulin (Cell Signaling no. 2144, 1:10,000). Secondary antibodies were conjugated to Alexa488, 546, 647 (1:1,000, Life Technologies A-11006) or HRP (1:1,000, Life Technologies A10549). EdU was administrated through intraperitoneal injection at 100 µl (5 mg ml −1 ) per 20 g mouse weight for 4 h before euthanasia. EdU was visualized by Click-iT EdU Alexa Fluor 647 Imaging Assay (Life Tech Molecular Probes). Tissues were processed as previously reported 10 , and mounted in ProLong Gold with DAPI (Life Tech). Images were captured on a Zeiss Axioplan2 using a Plan-Apochromat 20×/0.8 air objective, and processed using ImageJ and Adobe Photoshop CS5. Immunoblot was performed as previously described 38 .
RNA sequencing and quantitative PCR. Cells were lysed with TrizolLS (Invitrogen) and total RNA was isolated with the Direct-zol RNA MiniPrep kit (Zymo Research) and submitted to the Genomics Resources Core Facility of the Weill Cornell Medical College for quality control (determined using Agilent 2100 Bioanalyzer, with all samples passing the quality threshold of RNA integrity numbers (RIN) 8), library construction using IlluminaTruSeq Stranded mRNA Sample Prep Kit, and sequencing using Illumina HiSeq2000. Results were analysed as previously described 39 using TopHat to initiate mapping and Cufflinks for transcript assembly and expression level estimation with mm9 genome assembly as the reference genome. For RNA quantitative PCR, complementary DNAs were generated from 1 µg of total RNA using the SuperScript Vilo cDNA synthesis kit (Life Tech), diluted and used as templates for real-time PCR performed with the 7900HT Fast Real-Time PCR System (Applied Biosystems) and gene-specific primers listed in Supplementary Table 8 . GAPDH was used as a loading reference.
Cell culture. No cell lines were found in the database of commonly misidentified cell lines maintained by ICLAC and NCBI Biosample. The cell lines were not authenticated. The mouse SCC-SC cell lines isolated from early stage and malignant SCCs were generated previously in the Fuchs' laboratory 11 . The human HaCaT keratinocytes, A431 SCC and FaDu SCC cell lines were purchased from ATCC. Mouse HF-SCs were isolated and cultured as previously described 39 . All human cells were cultured in E Medium (Rheinwald and Beckett 1980). Mouse SCC and HF-SC cells were cultured in E intermediate calcium medium (contains 300 µM calcium); mouse epidermal keratinocytes were cultured in E low calcium medium (contains 50 µM calcium). For colony formation assay, equal numbers of cells were plated, in triplicate, onto mitomycin C-treated dermal fibroblasts. After 14 days in culture, cells were fixed and stained with 1% (w/v) rhodamine B (Sigma). For suspension cultures, cells were trypsinized and plated into the Costar Clear Flat Bottom Ultra Low Attachment Multiple Well Plates in culture medium. Apoptosis was assayed by the Pacific Blue Annexin V/SYTOX AADvanced Apoptosis Kit (Life tech Molecular Probes). The nucleotide analogue EdU (10 µM) was added to cell culture media 2 h before assaying by the Click-iT EdU Alexa Fluor 647 Flow Cytometry Assay Kit (Life tech Molecular Probes).
CRISPR in SCC cells. sgRNAs against the miR-21 locus were selected (4 each for mouse and human) from the GeCKO library, or 2 sgRNAs designed against putative miR-21 * targeting sites within the Phactr4 3 UTR (Supplementary Table 8 ) and cloned into lentiGuide-Puro vector 29 . sgRNAs against Scrambled sequences were used as controls and done side-by-side with sgRNAs against target sites throughout the experiments to rule out phenotypic changes due to nonspecific editing. Cas9-Blast vector was first transfected into previously established SCC cells 11 and selected with blasticidin (10 µg ml −1 ) to obtain stable SCC-Cas9 cells. Lenti-sgRNA-Puro vector was then transfected into SCC-Cas9 cells and selected with puromycin (3 µg ml −1 ) to obtain stable knockout pools. Surveyor assay and real-time PCR were performed to screen for the most effective sgRNA, which was then used to isolate single colonies to generate isogenic knockout cell lines. Genomic DNAs from single clones were isolated, from which the targeted miR-21 locus was PCR amplified and Sanger sequenced to confirm editing. Three independent clones were analysed and one representative clone was shown. The top three predicted off-target sites were also sequenced to rule out off-target mutations (Supplementary Table 8 ).
Luciferase assays and transfections. Dual Luciferase reporter assays in cultured HEK293FT cells were conducted using the Dual-Glo Luciferase Assay System following the manufacturer's protocol. The oligonucleotides for cloning wildtype or mutant miRNA-binding sites (MBS) into the 3 UTR of the pmiRGLO (Promega) dual luciferase reporter are listed in Supplementary Table 8 . Phactr4 3 UTR constructs were purchased from Origene (NM_001048183.1). Transfection was performed in a 96-well format with Effectene reagent (Qiagen), with a mixture of 5 ng Reporter plasmid + 100 ng SA-miRNA to overexpress miRNA.
Association between a gene's expression level and outcome: TCGA data analyses. To determine the potential association between a gene's expression level and survival in human HNSCC cancer, we used RNAseq tumour profiles and related clinical information available from The Cancer Genome Atlas data portal. The following algorithm was implemented. First, all tumours were sorted by a value of expression level assessed by the RSEM protocol (PMID: 21816040). Second, the sorted tumours were divided into two classes, as follows: the first k tumours with the lowest expression level were put in class 0 and the remaining N − k tumours were put in class 1 (N is used for a number of tumours in a data set; all possible twoclass separations were done for k = 1, . . . , N − 1). Third, for every class separation a difference in survival between two classes was estimated by a P value computed using the log-rank test method (PMID 5910392). The Kaplan-Meier curves that illustrate the differences in survival and correspond to the lowest observed P values are plotted. For miR-21 * association with patient prognosis and phactr4 level, all patients with available miR-21 * read data were ranked from high to low according to miR-21 * expression. The top 10% of the rank was taken as 'high' versus the bottom 10% taken as 'low' .
Statistics and reproducibility.
All experiments were independently repeated in the laboratory. Quantitative data were collected from experiments performed in at least triplicate, and expressed as mean ± s.d. Differences between groups were assayed using repeated-measure ANOVA tests for tumour growth curves, log-rank (Mantel-Cox) tests for survival curves, and two-tailed Student t-tests for the rest of the analysis. Differences were considered to be significant when P < 0.05. No statistical method was used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment.
